Salix Pharmaceuticals (SLXP) 134.88 $SLXP
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
TAL Education, Team Health Join The IBD 50 Resistance
at Investor's Business Daily - Fri Aug 01, 6:08PM CDT
Leading stocks took their licks in the past week, with only a small clique of IBD 50 stocks posting weekly gains. Among those, China-based TAL Education (XRS) hauled in an 11% gain to end the week at a new high. That left the chain of tutoring...
Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .
INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. to Cosmo Pharmaceuticals S.p.A
Business Wire - Fri Aug 01, 1:25PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix Pharmaceuticals"
in connection with the sale of the Company to a subsidiary of Cosmo Pharmaceuticals S.p.A.
Nektar's Loss Narrows in Q2, Beats Revenues, Retains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 12:53PM CDT
Nektar Therapeutics (NKTR) reported a loss of 26 cents per share in the second quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 37 cents.
Valeant Pharmaceuticals Earnings Up Y/Y, View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 12:35PM CDT
Valeant Pharmaceuticals' (VRX) reported second quarter 2014 cash earnings per share of $1.91 (excluding special items and non-cash expenses), up from the year-ago earnings of $1.34 per share.
Lifshitz & Miller Law Firm Announces Investigation of Design Within Reach, Inc., Family Dollar Stores, Inc., GFI Group Inc., Intermountain Community Bancorp, Rockwood Holdings, Inc., and Salix Pharmaceuticals Ltd.
PR Newswire - Thu Jul 31, 12:19PM CDT
Design Within Reach, Inc.
Tax Inversion: Boon for Firms & Investors, Bane for U.S. Treasury - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:41AM CDT
The U.S. Treasury may lose $19.5 billion over the next decade due to tax inversion.
SmarTrend Watching for Potential Pullback in Shares of Salix Pharmaceuticals After 2.87% Gain
Comtex SmarTrend(R) - Wed Jul 30, 4:39PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $131.88 to a high of $136.00. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $133.95 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.
Why Neptune Technologies (NEPT) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:42AM CDT
Neptune Technologies has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off.
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 20.8% (SLXP)
Comtex SmarTrend(R) - Tue Jul 29, 9:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 3 months, Salix Pharmaceuticals has returned 20.78% as of today's recent price of $131.73.
Lipocine Inc. (LPCN) Surges: Stock Moves 11.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 8:11AM CDT
Lipocine Inc. (LPCN) was a big mover last session, as the company saw its shares rise by roughly 12% on the day.
INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. - SLXP
PR Newswire - Mon Jul 28, 4:40PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) ("Salix Pharmaceuticals" in connection with the sale of the Company to a subsidiary of Cosmo Pharmaceuticals S.p.A.
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 11:47AM CDT
Questcor Pharmaceuticals Inc. (QCOR) reported second quarter 2014 earnings per share of $1.71. Excluding share-based compensation expenses, earnings came in at $1.76 per share. The Zacks Consensus Estimate was $1.93.
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
TAL Education, Team Health Join The IBD 50 Resistance
at Investor's Business Daily - Fri Aug 01, 6:08PM CDT
Leading stocks took their licks in the past week, with only a small clique of IBD 50 stocks posting weekly gains. Among those, China-based TAL Education (XRS) hauled in an 11% gain to end the week at a new high. That left the chain of tutoring...
Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .
INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. to Cosmo Pharmaceuticals S.p.A
Business Wire - Fri Aug 01, 1:25PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix Pharmaceuticals"
in connection with the sale of the Company to a subsidiary of Cosmo Pharmaceuticals S.p.A. Nektar's Loss Narrows in Q2, Beats Revenues, Retains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 12:53PM CDT
Nektar Therapeutics (NKTR) reported a loss of 26 cents per share in the second quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 37 cents.
Valeant Pharmaceuticals Earnings Up Y/Y, View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 12:35PM CDT
Valeant Pharmaceuticals' (VRX) reported second quarter 2014 cash earnings per share of $1.91 (excluding special items and non-cash expenses), up from the year-ago earnings of $1.34 per share.
Lifshitz & Miller Law Firm Announces Investigation of Design Within Reach, Inc., Family Dollar Stores, Inc., GFI Group Inc., Intermountain Community Bancorp, Rockwood Holdings, Inc., and Salix Pharmaceuticals Ltd.
PR Newswire - Thu Jul 31, 12:19PM CDT
Design Within Reach, Inc.
Tax Inversion: Boon for Firms & Investors, Bane for U.S. Treasury - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:41AM CDT
The U.S. Treasury may lose $19.5 billion over the next decade due to tax inversion.
SmarTrend Watching for Potential Pullback in Shares of Salix Pharmaceuticals After 2.87% Gain
Comtex SmarTrend(R) - Wed Jul 30, 4:39PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $131.88 to a high of $136.00. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $133.95 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.
Why Neptune Technologies (NEPT) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:42AM CDT
Neptune Technologies has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off.
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 20.8% (SLXP)
Comtex SmarTrend(R) - Tue Jul 29, 9:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 3 months, Salix Pharmaceuticals has returned 20.78% as of today's recent price of $131.73.
Lipocine Inc. (LPCN) Surges: Stock Moves 11.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 8:11AM CDT
Lipocine Inc. (LPCN) was a big mover last session, as the company saw its shares rise by roughly 12% on the day.
INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. - SLXP
PR Newswire - Mon Jul 28, 4:40PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) ("Salix Pharmaceuticals"
in connection with the sale of the Company to a subsidiary of Cosmo Pharmaceuticals S.p.A. Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 11:47AM CDT
Questcor Pharmaceuticals Inc. (QCOR) reported second quarter 2014 earnings per share of $1.71. Excluding share-based compensation expenses, earnings came in at $1.76 per share. The Zacks Consensus Estimate was $1.93.
